Gilgamesh Pharmaceuticals

Overview

• HeadquartersNew York City¹
• Websitewww.gilgameshpharmaceutical.com
• Incorporated inDE⁶
• Business address201 Dam Trail #1349, Linville, Nc 28646⁶
• Legal formCorporation⁴
• LEI549300ZGW0UFISUHRL10⁴
• StatusActive⁴
• LEI statusLapsed (not renewed)⁴
• Registered addressC/O COGENCY GLOBAL INC., 19904 Dover, United States⁴
• Registered withDivision of Corporations, Department of State, 7522615⁴

See how the biggest companies compare on our leaderboards

Gilgamesh Pharmaceuticals is a pharmaceutical company that is developing psychedelic and related drugs as medicines. It is a "discovery stage" company and is focused on developing new chemical entities.³

Leadership

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorAndrew Kruegel named Feb 18, 2022 to May 19, 2022⁷
• Executive OfficerGerard Marek named May 19, 2022⁷
• Executive Officer, DirectorJonathan Sporn named Feb 18, 2022 to May 19, 2022⁷
• Executive OfficerLaszlo Kiss named May 19, 2022⁷
• Executive OfficerThomas Kevin Murphy named May 19, 2022⁷
• Executive OfficerYoni Falkson named May 19, 2022⁷
• DirectorAmy Kruse named Feb 18, 2022 to May 19, 2022⁷
• DirectorGaetano Kevin Crupi named May 19, 2022⁷
• DirectorPhil Skolnick named Feb 18, 2022 to May 19, 2022⁷
• DirectorRobert Berman named Feb 18, 2022 to May 19, 2022⁷

Timeline

1. 2019Founded Founded¹

Calendar

Drug trials and FDA: recently

1. Mar 4, 2025Phase 2 trial completed Phase 2 trial of GM-1020 in Major Depressive Disorder: primary completion Mar 4, 2025, results posted May 8, 2026 (ClinicalTrials.gov NCT06309277).⁸

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

2 filings to the SEC since October 2021: 2 private raises. The latest 2:

1. May 19, 2022D EDGAR
2. Feb 18, 2022D EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. May 16, 2022Raised $13.8 million in a private offering of equity⁷ Form D: $50 million offered in all Form D
2. Feb 4, 2022Filed a private offering of equity⁹ Form D: $951 offered in all Form D

Federal awards

Obligated amounts from USAspending.gov¹⁰, by calendar year, 2024–2025, for its registration. Obligations are what agencies committed, not always what was paid out. Contracts pay for goods and services; grants, loans and direct payments are assistance. Loans are charted at the face value of the loans listed here. An award’s amount below is its lifetime total, and some began before the years charted.

Largest grants

1. Mar 1, 2024$5.4M from National Institutes of Health: Drug Abuse And Addiction Research Programs; Drug Use And Addiction Research Programs¹¹ To GILGAMESH PHARMACEUTICALS INC Award UG3DA060053

SEC filer profile

How Gilgamesh Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARGilgamesh Pharmaceuticals, Inc.²
• CIK0001817048
• Employer ID (EIN)84-2552195²
• Incorporated inDelaware²
• Fiscal year endsDecember 31²
• Business address201 Dam Trail #1349, Linville, NC 28646²
• Phone347-967-6831²
• On EDGAR sinceJul 10, 2020²
• Filings7 in all: D (6), D/A (1)²

Links

• Websitewww.gilgameshpharmaceutical.com¹
• LinkedInwww.linkedin.com/company/gilgamesh-pharmaceuticals¹
• WikipediaGilgamesh Pharmaceuticals
• WikidataQ133094039
• SEC EDGARCIK 1817048